Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00806221 · ClinicalTrials.gov registry record · Phase 2
An Open-Label Study Investigating the Effects of Early Skin Barrier Protection on the Development of Atopic Dermatitis
A Phase 2 study of Atopic Dermatitis, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT00806221: Completed Phase 2 study of Atopic Dermatitis, sponsored by Oregon Health and Science University.
NCT00806221 is a Phase 2 study of Atopic Dermatitis that has completed, run by Oregon Health and Science University. The registered enrollment target is 22 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00806221, a Phase 2 study of Atopic Dermatitis, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether early use of a bland emollient in newborns, prior to the clinical signs of skin disease, will delay the onset or prevent the development of atopic dermatitis.
Conditions Studied
Interventions
- DRUG emollient (Cetaphil cream)
Study Locations (1)
Oregon
- Oregon Health & Science University, Department of Dermatology - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2006-11 |
| Est. Completion | 2009-11 |
| Phase | Phase 2 |
What the finished NCT00806221 record still lists
NCT00806221 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 1 intervention - of which emollient (Cetaphil cream) is the first listed.
NCT00806221 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT00806221 about?
NCT00806221 is a clinical study titled "An Open-Label Study Investigating the Effects of Early Skin Barrier Protection on the Development of Atopic Dermatitis". The purpose of this study is to determine whether early use of a bland emollient in newborns, prior to the clinical signs of skin disease, will delay the onset or prevent the development of atopic dermatitis.
What is the current status of trial NCT00806221?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2006-11. Estimated completion is 2009-11.
What conditions does trial NCT00806221 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT00806221?
The interventions under investigation include: emollient (Cetaphil cream) (DRUG).
Who is sponsoring clinical trial NCT00806221?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00806221 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00806221's enrollment target sits among peer trials
22 132nd of 150 higher than 18 of 150 other Atopic Dermatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Cardamom and Topical Roseomonas in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
A Study Evaluating TRIV-509 in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia